Chemotherapy in the elderly

Aging Health

Volumn 3, Issue 2, 2007, Pages 165-175

  Lichtman, Stuart M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Aging; Assessment; Cancer; Chemotherapy; Clinical trials; Comorbidity; Elderly; Frailty; Function; Pharmacokinetics

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450 3A4; DACARBAZINE; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; FLUDARABINE; GEMCITABINE; GROWTH FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PLATINUM COMPLEX; PREDNISONE; RITUXIMAB; TAXANE DERIVATIVE; VINCRISTINE;

ADJUVANT THERAPY; ANEMIA; BLOOD SAMPLING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL TRIAL; COGNITIVE DEFECT; COLON CANCER; COMORBIDITY; CREATININE CLEARANCE; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE FREE SURVIVAL; DOSE CALCULATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ELDERLY CARE; FRAIL ELDERLY; FUNCTIONAL STATUS; GERIATRIC ASSESSMENT; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HEMATOPOIESIS; HOME ENVIRONMENT; HUMAN; KIDNEY DYSFUNCTION; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MENTAL HEALTH; MONOTHERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; NUTRITIONAL STATUS; OVERALL SURVIVAL; PANCREAS CANCER; POLYPHARMACY; PRACTICE GUIDELINE; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SOCIAL SUPPORT;

EID: 34247235789     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.3.2.165     Document Type: Review

References (101)

1. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349(9064), 1498-1504 (1997).
2. Franceschi S, La Vecchia C: Cancer epidemiology in the elderly. Crit. Rev. Oncol. Hematol. 39(3), 219-226 (2001).
3. Balducci L. Extermann M: Cancer and aging. An evolving panorama. Hematol. Oncol. Clin. North Am. 14(1), 1-16 (2000).
4. Jernal A, Murray T, Ward E et al.: Cancer Statistics 2005. CA Cancer J. Clin. 55(1), 10-30 (2005).
5. Yancik R, Ries LA: Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol. Oncol. Clin North Am. 14(1), 17-23 (2000).
6. Hamerman D: Toward an understanding of frailty. Ann. Intern. Med. 130(11), 945-950 (1999).
7. Fried LP, Tangen CM, Walston J et al.: Frailty in older adults: evidence for a phenotype. J. Gerontol. A. Biol. Sci. Med. Sci. 56(3), M146-M156 (2001).
8. Lichtman SM:Therapy insight: Therapeutic challenges in the treatment of elderly cancer patients. Nat. Clin. Pract. Oncol. 3(2), 86-93 (2006).
9. Salvioli S, Capri M, Valensin S et al.: Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology. Curr. Pharm. Des. 12(24), 3161-3171 (2006).
10. Fulop T, Tessier D, Carpentier A: The metabolic syndrome. Pathol. Biol. (Paris) 54(7), 375-386 (2006).
11. Talarico L, Chen G, Pazdur R: Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J. Clin. Oncol. 22(22), 4626-4631 (2004).
12. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341(27), 2061-2067 (1999).
13. Monfardini S, Aversa SM, Zoli V et al.: Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. Ann. Oncol. 16(8), 1352-1358 (2005).
14. Balducci L, Stanta G: Cancer in the frail patient. A coming epidemic. Hematol. Oncol. Clin. North Am. 14(1), 235-250 (2000).
15. Yuen GJ: Altered pharmacokinetics in the elderly. Clin. Geriatr. Med. 6, 257-267 (1990).
16. Baker SD, Grochow LB: Pharmacology of cancer chemotherapy in the older person. Clin. Geriatr. Med. 13(1), 169-183 (1997).
17. Kastrissios H, Blaschke TF: Medication compliance as a feature in drug development. Annu. Rev. Pharmacol. Toxicol. 37, 451-475 (1997).
18. DeMario MD, Ratain MJ: Oral chemotherapy: rationale and future directions. J. Clin. Oncol. 16(7), 2557-2567 (1998).
19. Egorin MJ: Cancer pharmacology in the elderly. Semin. Oncol. 20, 43-49 (1993).
20. Rossman I: Clinical geriatrics. Second Edition. Lippincott, Philadelphia, USA (1979).
21. Sawhney R, Sehl M, Naeim A: Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 11(6), 449-460 (2005).
22. Baker SD, van Schaik RH, Rivory LP et al.: Factors affecting cytochrome P-450 3A activity in cancer patients. Clin. Cancer Res. 10(24), 8341-8350 (2004).
23. Sotanlemi EA, Arranto AJ, Pelkonen O, Psanen M: Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions. Clin. Pharmacol. Ther. 61, 331-339 (1997).
24. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
25. Extermann M, Yoder J, Overcash J et al.: Influence of p450-metabolized concomitant medications on toxicity from chemotherapy in older cancer patients. Proc. Am. Soc. Clin. Oncol. 22, 2937a (2003).
26. Flockhart DA, Rae JM: Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenetics J. 3(1), 3-5 (2003).
27. Rieseman C: Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 15(6 pt 2), 84S-99S (1995).
28. Michalets EL: Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18(1), 84-112 (1998).
29. Evans W, Schentag J, Jusko W: Applied pharmacokinetics, principles of therapeutic drug monitoring, 3rd Edition. Applied Therapeutics, Inc. Vancouver, WA, USA (1994).
30. Brenner BM, Meyer GW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N. Engl. J. Med. 307, 652-659 (1982).
31. Tauchi H, Tsuboi K, Okutoni J: Age changes in the human kidney of the different races. Gerontology 17, 87-97 (1971).
32. Evers BM, Townsend CMJ, Thompson JC: Organ physiology of aging. Surg. Clin. North Am. 74, 23-39 (1994).
33. Gelman RS, Taylor SG 4th: Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J. Clin. Oncol. 2(12), 1404-1413 (1984).
34. Swedko PJ, Clark HD, Paramsothy K, Akbari A: Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch. Intern. Med. 163(3), 356-360 (2003).
35. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16(1), 31-41 (1976).
36. Jellife RW: Estimation of creatinine, clearance when urine cannot be collected. Lancet 1(7706), 975-976 (1971).
37. Smythe M, Hoffman J, Kizy K, Dmuchowski C: Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. Am. J. Hosp. Pharm. 51, 198-204 (1994).
38. Marx GM, Steer CB, Galani E et al.: Evaluation of the Cockroft Gault, Jelliffe and Wright formulae in estimating renal function in elderly patients. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 21, 1486a (2002).
39. Burkhardt H, Bojarsky G, Gretz N, Gladisch R: Creatinine clearance, Cockcroft-Gautt formula and cystatin C: estimators of true glomerular filtration rate in the elderly? Gerontology 48(3), 140-146 (2002).
40. Levey AS, Coresh J, Greene T et al.: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 145(4), 247-254 (2006).
41. Marx GM, Blake GM, Galani E et al.: Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann. Oncol. 15(2), 291-295 (2004).
42. Kintzel PE, Dorr RT: Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat. Rev. 21(1), 33-64 (1995).
43. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M: International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency Eur. J. Cancer 43, 14-34 (2007).
44. Charlson ME, Pompel P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40(5), 373-383 (1987).
45. Satariano WA, Ragland DA: The effect of comorbidity, on 3-year survival of women with primary breast cancer. Ann. Intern. Med. 120, 104-110 (1994).
46. Yancik R, Wesley MN, Ries LA et al.: Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 82(11), 2123-2134 (1998).
47. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L: Comorbidity and functional status are independent in older cancer patients. J. Clin. Oncol. 16(4), 1582-1587 (1998).
48. Rockwood K, Stadnyk K, MacKnight C, McDowell I, Hebert R, Hogan DB: A brief clinical instrument to classify frailty in elderly people. Lancet 353(9148), 205-206 (1999).
49. Reuben DB, Rubenstein LV, Hirsch SH, Hays RD: Value of functional status as a predictor of mortality: results of a prospective study. Am. J. Med. 93(6), 663-669 (1992).
50. Repetto L, Vercelli M, Simoni C et al.: Comorbidity among elderly patients with and without cancer. Proc. Am. Soc. Clin. Onc. 13, 1625a (1994).
51. Extermann M, Aapro M, Bernabei R et al.: Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit. Rev. Oncol. Hematol. 55(3), 241-252 (2005).
52. Hurria A, Gupta S, Zauderer M et al.: Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104(9), 1998-2005 (2005).
53. Boggs DR, Patrene KD: Hematopoiesis and aging III: anemia and a blunted erythropoietic response to hemorrhage in aged mice. Am. J. Hematol. 19(4), 327-338 (1985).
54. Rothstein G, Christensen RD, Nielsen BR: Kinetic evaluation of the pool sizes and proliferative response of neutrophils in bacterially challenged aging mice. Blood 70(6), 1836-1841 (1987).
55. Baraldi-Junkins CA, Beck AC, Rothstein G: Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol. Oncol. Clin. North Am. 14(1), 45-61, (2000).
56. Ania BJ, Suman VJ, Fairbanks VF, Rademacher DM, Melton LJ 3rd: Incidence of anemia in older people: an epidemiologic study in a well defined population. J. Am. Geriatr. Soc. 45(7), 825-831 (1997).
57. Chaves PH, Ashar B, Guralnik JM, Fried LP: Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to deftne anemia in older people be reevaluated? J. Am. Geriatr. Soc. 50(7), 1257-1264 (2002).
58. Ania BJ, Suman VJ, Fairbanks VF, Melton LJ 3rd: Prevalence of anenmia in medical practice: community versus referral patients. Mayo Clin. Proc. 69(8), 730-735 (1994).
59. Balducci L, Yates J: General guidelines for the management of older patients with cancer. Oncology (Williston Park) 14(11A), 221-227 (2000).
60. Crawford J, Dale DC, Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100(2), 228-237 (2004).
61. Schild SE, Stella PJ, Geyer SM et al.: the outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J. Clin. Oncol. 21(17), 3201-3206 (2003).
62. Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA: Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J. Clin. Oncol. 22(2), 262-268 (2004).
63. Lyman GH, Delgado DJ: Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98(11), 2402-2409 (2003).
64. Balducci L, Repetto L: Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer 100(1), 6-11 (2004).
65. Balducci L, Lyman GH: Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J. Clin. Oncol. 19(5), 1583-1585 (2001).
66. Smith TJ, Khatcheressian J, Lyman GH et al.: 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24(19), 3187-3205 (2006).
67. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J. Clin. Oncol. 21(24), 4524-4531 (2003).
68. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N. Engl. J. Med. 304, 101-105 (1981).
69. Chrischilles EA, Link BK, Scott SD, Delgado DJ, Fridman M: Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control 10(5), 396-403 (2003).
70. Dixon DO, Neilan B, Jones S et al.: Effect of age on therapeutic outcome in advanced diffuse histocytic lymphoma: the Southwest Oncology Group experience. J. Clin. Oncol. 4, 295-305 (1986).
71. Vose JM, Armitage JO, Welsenburger DD et al.: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 6(12), 1838-1844 (1988).
72. Johansson JE, Adami HO, Anderson SO, Bergstrom R, Holmberg L, Krusemo UB: High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 267(16), 2191-2196 (1992).
73. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT: Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J. Natl. Cancer Inst. 92(8). 613-621 (2000).
74. Cohen HJ, Feussner JR, Weinberger M et al.: A controlled trial of inpatient and outpatient geriatric evaluation and management. N. Engl. J. Med. 346(12), 905-912 (2002).
75. High K, Bradley S, Loeb M, Palmer R, Quagliarello V, Yoshikawa T: A new paradigm for clinical investigation of infectious syndromes in older adults: assessing functional status as a risk factor and outcome measure. J. Am. Geriatr. Soc. 53(3), 528-535 (2005).
76. Crawford J: Pegfilgrastim: the promise of pegylation fulfilled. Ann. Oncol. 14(1), 6-7 (2003).
77. Crawford J, Ozer H, Stoller R et al.: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N. Engl. J. Med. 325, 164-170 (1991).
78. Borkowski JM, Duerr M, Donehower RC et al.: Relation between age and clearance rate of nine investigational anticancer drugs from Phase I pharmacokinetic data. Cancer Chemother. Pharmacol. 33, 493-496 (1994).
79. Grever MR, Grieshaber CK: Toxicology by organ system. In: Cancer medicine. 5th Edition. Holland JF, Frei E (Eds). B.C. Decker, Hamilton, Ontario, New York, USA (2000).
80. Vestal RE: Aging and pharmacology. Cancer 80(7), 1302-1310 (1997).
81. Kivisto KT, Kroemer HK, Eichelbaum M: The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol. 40(6), 523-530 (1995).
82. King RS: Drug interactions with cancer chemotherapy. Cancer Pract. 3(1), 57-59 (1995).
83. Flockhart DA, Tanus-Santos JE: Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch. Intern. Med. 162(4), 405-412 (2002).
84. Ratain MJ, Staubus AE, Schilsky RL, Malspeis L: Limited sampling models for amonafide pharmacokinetics. Proc. AACR 29, 766a (1988).
85. Mick R, Gupta E, Vokes EE, Ratain MJ: Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J. Clin. Oncol. 14(7), 2012-2019 (1996).
86. Minami H, Beijnen JH, Verweij J, Ratain MJ: Limited sampling model for area under the concentration time curve of total topotecan. Clin. Cancar Res. 2(1), 43-46 (1996).
87. Ratain MJ, Robert J, van der Vijgh WJ: Limited sampling models for doxorubicin pharmacokinetics. J. Clin. Oncol. 9(5), 871-876 (1991).
88. Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abram JS, Van Echo DA: A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res. 49(11), 3129-3133 (1989).
89. Ratain MJ, Staubus AE, Schilsky RL, Malspeis L: Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res. 48(14), 4127-4130 (1988).
90. Ratain MJ, Vogeizang NJ: Limited sampling model for vinblastine pharmacokinetics. Cancer Treat. Res. 71(10), 935-939 (1987).
91. van Warmerdam, LJ, ten Bokkel Huinink WW, Maes RA, Beijnen JH: Limited-sampling models for anticancer agents. J. Cancer Res. Clin. Oncol. 120(7), 427-433 (1994).
92. Tranchand B, Amsellem C, Chatelut E et al.: A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother. Pharmacol. 43(4), 316-322 (1999).
93. van Warmerdam LJ, Verweij J, Rosing H, Schellens JH, Maes RA, Beijnen JH: Limited sampling models for topotecan pharmacokinetics. Ann. Oncol. 5. 259-264 (1994).
94. Aarons L: Population pharmacokinetics: theory and practice. Br. J. Clin. Pharmacol. 32(6), 669-670 (1991).
95. Lichtman SM, Hollis D, Miller AA et al.: Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J. Clin. Oncol. 24(12), 1846-1851 (2006).
96. Extermann M, Balducci L, Lyman GH: What threshold for adjuvant therapy in older breast cancer patients? J. Clin. Oncol. 18(8), 1709-1717 (2000).
97. Lichtman SM: Guidelines for the treatment of elderly cancer patients. Cancer Control 10(6), 445-453 (2003).
98. Gridelli C, Aapro M, Ardizzoni A et al.: Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J. Clin. Oncol. 23, 3125-3137 (2005).
99. Sargent DJ, Goldberg RM, Jacobson SD et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med. 345, 1091-1097 (2001).
100. Muss HB, Woolf S, Berry D et al.: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293, 1073-1081 (2005).
101. Feugier P, van Hoof A, Sebban C et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 23, 4117-4126 (2005).